I don't put much credence in the Van L report. I am sticking to 2018. The unknowable is recruitment. However given the feedback from the FDA there should be a lot of excitement around the phase 3 on smoking cessation and recruitment should be much more rapid than the phase 2. There will, of course, be a much larger number to recruit. I would think Nadolol should be on market eighteen months after last patient, first dose, ie, end of recruitment. I was particularly encouraged by the remarks that the FDA had made suggestions about time saving in trials.
Add to My Watchlist
What is My Watchlist?
